Godavari Biorefineries saw its share price jump as much as 13% to ₹258.87 on the NSE following the grant of a patent from the Chinese Patent Office. The patent covers the use of compounds that inhibit V-ATPase activity in cells, which are linked to antiviral properties. The stock gained 3.16% over the past week, reflecting renewed investor interest after the announcement, according to livemint.com.
The company disclosed the patent approval in an exchange filing, highlighting the significance of the antiviral compound in its portfolio. The patent specifically relates to compounds that inhibit V-ATPase activity, a mechanism relevant to antiviral treatments. This regulatory milestone in China, a key market, underscores Godavari Biorefineries’ ongoing research and development efforts in bioactive compounds, as reported by thehindubusinessline.com.
The patent grant is notable given the growing global focus on antiviral therapies and the competitive landscape of biorefinery companies innovating in this space. Godavari Biorefineries’ stock performance contrasts with mixed trends in the sector, as the company leverages intellectual property rights to strengthen its market position. The development aligns with broader trends of Indian biopharma firms securing international patents to enhance their global footprint, according to livemint.com.
Godavari Biorefineries’ share price rally on the NSE on Wednesday marks a significant response to the Chinese patent grant. The company’s next quarterly results, expected later this year, will provide further insight into how this patent and related R&D investments impact its financial performance, thehindubusinessline.com noted.